- Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
- Explain that a retrospective study showed a benefit for bevacizumab in patients with recurrent ovarian cancer, similar to benefits seen in prior clinical trials.
- Note that the greatest benefit from bevacizumab was seen in platinum-sensitive ovarian cancer and those receiving second- or third-line treatment in combination with chemotherapy.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.